Analysis of Clinical Outcome for Cytogenetic Subgroups
| Subgroup* . | DFS . | Survival . | ||||||
|---|---|---|---|---|---|---|---|---|
| N . | Median (yr) . | Probability of CCR at 5 yr (95% CI) . | P† . | N . | Median (yr) . | Probability of Survival at 5 yr (95% CI) . | P† . | |
| Normal | 65 | 2.3 | .38 (.26-.53) | 79 | 2.9 | .37 (.26-.50) | ||
| t(9;22)(q34;q11) | 52 | 0.9 | .08 (.03-.21) | <.001 | 67 | 1.3 | .11 (.05-.23) | <.001 |
| +21 | 27 | 1.3 | .29 (.10-.58) | .11 | 32 | 1.5 | .26 (.10-.51) | .06 |
| +8 | 20 | 0.6 | .15 (.04-.41) | .007 | 23 | 1.3 | .12 (.03-.34) | .004 |
| t(4;11)(q21;q23) | 13 | 0.5 | .15 (.03-.54) | .002 | 17 | 0.8 | .18 (.03-.58) | <.001 |
| −7 | 8 | 1.1 | .25 (.07-.59) | .42 | 14 | 1.3 | .14 (.04-.40) | .01 |
| del(9p) or t(9p) | 25 | 0.9 | .44 (.23-.67) | .82 | 28 | 1.3 | .38 (.21-.59) | .58 |
| del(12p) or t(12p)‡ | 9 | >4.7 | .76 (.29-.94) | .09 | 11 | 6.8 | .82 (.46-.96) | .10 |
| t(14q11-q13)‡ | 9 | >7.3 | .78 (.45-.94) | .05 | 9 | >7.4 | .78 (.45-.94) | .04 |
| Subgroup* . | DFS . | Survival . | ||||||
|---|---|---|---|---|---|---|---|---|
| N . | Median (yr) . | Probability of CCR at 5 yr (95% CI) . | P† . | N . | Median (yr) . | Probability of Survival at 5 yr (95% CI) . | P† . | |
| Normal | 65 | 2.3 | .38 (.26-.53) | 79 | 2.9 | .37 (.26-.50) | ||
| t(9;22)(q34;q11) | 52 | 0.9 | .08 (.03-.21) | <.001 | 67 | 1.3 | .11 (.05-.23) | <.001 |
| +21 | 27 | 1.3 | .29 (.10-.58) | .11 | 32 | 1.5 | .26 (.10-.51) | .06 |
| +8 | 20 | 0.6 | .15 (.04-.41) | .007 | 23 | 1.3 | .12 (.03-.34) | .004 |
| t(4;11)(q21;q23) | 13 | 0.5 | .15 (.03-.54) | .002 | 17 | 0.8 | .18 (.03-.58) | <.001 |
| −7 | 8 | 1.1 | .25 (.07-.59) | .42 | 14 | 1.3 | .14 (.04-.40) | .01 |
| del(9p) or t(9p) | 25 | 0.9 | .44 (.23-.67) | .82 | 28 | 1.3 | .38 (.21-.59) | .58 |
| del(12p) or t(12p)‡ | 9 | >4.7 | .76 (.29-.94) | .09 | 11 | 6.8 | .82 (.46-.96) | .10 |
| t(14q11-q13)‡ | 9 | >7.3 | .78 (.45-.94) | .05 | 9 | >7.4 | .78 (.45-.94) | .04 |
Abbreviation: CI, confidence interval.
A given patient might have several abnormalities present, eg, a patient with t(14q11-q13) had t(9;22) and other abnormalities.
P value from logrank test comparing clinical outcome for each specific cytogenetic abnormality and the normal group.
Excluding patients with t(9;22).